{
  "docId": "019dd923-622b-71dc-a6da-f68e9cf62b7a",
  "docSlug": "d8035db2dcbb",
  "documentTitle": "Bayer AG (BAYN)",
  "authorId": "04_Greenlight_Capital",
  "authorName": "David Einhorn",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2016-11-28 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 16,
  "pageCount": 48,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "other",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a timeline to illustrate that major revenue-generating products are not facing immediate patent cliffs.",
  "elementsJson": [
    "headline_text",
    "timeline_visual",
    "paragraph"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6da-f68e9cf62b7a/16",
  "deckHref": "/decks/019dd923-622b-71dc-a6da-f68e9cf62b7a",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6da-f68e9cf62b7a.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-f68e9cf62b7a#slide-16",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Not only are its key products in growth mode, but Bayer also has a favorable patent cliff, with nothing significant expiring for many years including Eylea and Xarelto.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f40-73bb-a610-9e3ea1871384",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.76,
        "x": 0.12,
        "y": 0.23
      },
      "kind": "diagram",
      "text": "Timeline from 2017 to 2029",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "804c1df9-3a9a-445c-aba8-cc5658f3c058",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.62,
        "x": 0.27,
        "y": 0.27
      },
      "kind": "other",
      "text": "Xofigo (Cancer, €1B), Xarelto (Stroke prevention, €5B), Eylea (Wet AMD, €2.5B), Mirena (IUD, €1.2B)",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "294f5471-991d-4efc-93c1-1d6003023aeb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.76,
        "x": 0.12,
        "y": 0.49
      },
      "kind": "paragraph",
      "text": "Not only are its key products in growth mode, but Bayer also has a favorable patent cliff, with nothing significant expiring for many years including Eylea and Xarelto.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b20821f-45c7-43de-b901-09b49b869345",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.62,
        "x": 0.19,
        "y": 0.08
      },
      "kind": "title",
      "text": "Plenty of breathing room",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43ffdd0d-eec5-48f9-9c04-ac2af86b071a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.22,
        "x": 0.39,
        "y": 0.16
      },
      "kind": "title",
      "text": "Patent Expiration",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81aaac66-f370-4bd2-a0b8-d396604235f3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "ca6f8357-9755-40f3-b173-d2601501cf74",
      "evidence": "The slide mentions a 'Timeline from 2017 to 2029' and lists several drugs with their revenues, which is similar to a waterfall chart.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "396e81c4-dd23-4bdf-bbf8-e502f3f55252",
      "evidence": "Visual timeline of patent expirations",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "9db21285-546a-49b1-882e-f7933ceca20c",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "Highlighting Bayer's growth potential",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}